SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it has published its 2024 Corporate Sustainability Report, highlighting the company’s efforts to build a sustainable and inclusive future.
“iRhythm’s core mission is to create a better world for patients by delivering better health and better insights through our trusted solutions and innovative technologies,” said Sumi Shrishrimal, iRhythm’s Chief Risk Officer and leader of Sustainability and Impact. “We accomplish this by being a responsible, ethical, and inclusive company dedicated to the highest standards of quality and excellence across our business as we execute upon our long-term strategic growth plan. I am so proud of the work our teams do every day, and our 2024 Corporate Sustainability Report reflects how we make cardiac monitoring more accessible, how we enable providers to better detect and prevent disease, and how we impact our communities as a global company.”
The 2024 Corporate Sustainability Report details sustainability accomplishments across four key pillars:
For more information about iRhythm’s corporate sustainability efforts, please visit our Corporate Sustainability page here.
About iRhythm Technologies
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. To learn more, please visit https://www.irhythmtech.com/.
Investor Contact
Stephanie Zhadkevich
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Kassandra Perry
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$173.81 |
Daily Change: | 6.25 3.73 |
Daily Volume: | 324,164 |
Market Cap: | US$5.580B |
August 18, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load